(Q24200353)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Regular treatment with salmeterol for chronic asthma: serious adverse events

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

The cardio-toxicity of isoprenaline during hypoxia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Eosinophilic Inflammation in Asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Interaction revisited: the difference between two estimates

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonists

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Interactions between corticosteroids and beta2-agonists

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Recovery from bronchoconstriction and bronchodilator tolerance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Airway hyperresponsiveness as a determinant of the early asthmatic response to inhaled allergen

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Improved lung function and symptom control with formoterol on demand in asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-we

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Efficacy and tolerability of formoterol Turbuhaler in children.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Serious asthma exacerbations in asthmatics treated with high-dose formoterol

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Beta-agonist intrinsic efficacy: measurement and clinical significance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Bioequivalence of inhaled formoterol fumarate assessed from pharmacodynamic, safety and urinary pharmacokinetic data

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Asthma. From bronchoconstriction to airways inflammation and remodeling

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Airway hyperresponsiveness in asthma: not just a matter of airway inflammation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Beta-adrenoceptors and the epithelial layer in airways

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Systemic effects of salbutamol and salmeterol in patients with asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Beta-adrenergic receptors and their regulation.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Role of Autonomic Nervous System and the Cough Reflex in the Increased Responsiveness of Airways in Patients with Obstructive Airway Disease*

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Further observations on the cardiotoxicity of isoprenaline during hypoxia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Regular inhaled beta-agonist treatment in bronchial asthma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol suspension aerosol. Comparison with formoterol solution aerosol for 12 weeks in asthmatic patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Subsensitivity to the bronchodilator action of albuterol produced by chronic administration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

The pathology of asthma, with special reference to changes in the bronchial mucosa

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Salbutamol: a new, selective beta-adrenoceptive receptor stimulant

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Potential masking effects of salmeterol on airway inflammation in asthma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Hypokalemia from Beta2-Receptor Stimulation by Circulating Epinephrine

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Observations on recent increase in mortality from asthma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

2 new groups of selective stimulants of adrenergic beta-receptors.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A model of the mechanics of airway narrowing.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Protective effect and duration of action of formoterol aerosol on exercise-induced asthma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Sustained improvement in asthma with long-term use of formoterol fumarate.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-du

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Long-term efficacy of formoterol compared to salbutamol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol Delivered via the Dry Powder Aerolizer® Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Acute pulmonary injury in association with amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol induces tolerance to the bronchodilating effect of Salbutamol following methacholine-provocation test in asthmatic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol provides long-lasting protection against exercise-induced bronchospasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol used as needed in patients with intermittent or mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Traditional and patient-centred outcomes with three classes of asthma medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Safety of formoterol in children and adolescents: experience from asthma clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol Turbuhaler as reliever medication in patients with acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Lack of Evidence for Beta-2 Receptor Selectivity: a Study of Metaproterenol, Fenoterol, Isoproterenol, and Epinephrine in Patients with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Characterization of airway plugging in fatal asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

Comparison of the Bronchodilator Effect of Inhaled Short- and Long-Acting beta(2)-Agonists in Children with Bronchial Asthma: A Randomised Trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Current issues with beta2-adrenoceptor agonists: historical background.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aeroli

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

The effect of formoterol over 24 h in patients with asthma: the role of enantiomers

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Formoterol and asthma exacerbations

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A comparison of salmeterol and formoterol in attenuating airway responses to short-acting β2-agonists

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Miflonide/Foradil via Aerolizer compared with other anti-inflammatory and anti-obstructive therapeutic regimens

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Single-dose comparison of formoterol (Oxis) Turbuhaler 6 microg and formoterol Aerolizer 12 microg in moderate to severe asthma: a randomised, crossover study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

The safety and efficacy of formoterol (Oxis) turbuhaler plus budesonide (Pulmicort) turbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

[Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone].

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017186

Tolerance to beta-agonists during acute bronchoconstriction

29 November 2018

1 reference

12 December 2020

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment

1 reference

12 December 2020

Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma

1 reference

12 December 2020

Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma

1 reference

12 December 2020

The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma

1 reference

12 December 2020

Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients

1 reference

12 December 2020

Onset and duration of action of single doses of formoterol inhaled via Turbuhaler

1 reference

12 December 2020

Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma

1 reference

12 December 2020

The structure of large and small airways in nonfatal and fatal asthma

1 reference

12 December 2020

Rapid onset of action of inhaled formoterol in asthmatic patients

1 reference

12 December 2020

Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study

1 reference

12 December 2020

Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting beta2-agonist therapy

1 reference

12 December 2020

Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.).

1 reference

12 December 2020

Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily

1 reference

12 December 2020

Clinical effects of epinephrine by inhalation; a survey

1 reference

12 December 2020

Inflammation and airway function in asthma: what you see is not necessarily what you get

1 reference

12 December 2020

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

1 reference

12 December 2020

The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma

1 reference

12 December 2020

Regular inhaled salbutamol and airway responsiveness to allergen

1 reference

12 December 2020

HLA-DR and ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis

1 reference

12 December 2020

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

12 December 2020

Asthma deaths in New Zealand: whodunnit?

1 reference

12 December 2020

The extrapulmonary effects of increasing doses of formoterol in patients with asthma

1 reference

12 December 2020

Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol

1 reference

12 December 2020

Myofibroblasts and subepithelial fibrosis in bronchial asthma

1 reference

12 December 2020

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist

1 reference

12 December 2020

Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo

1 reference

12 December 2020

Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration

1 reference

12 December 2020

Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma

1 reference

12 December 2020

Characteristics of the Inflammatory response in bronchial lavage fluids from patients with status asthmaticus

1 reference

12 December 2020

Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children

1 reference

12 December 2020

[Dry powdered formoterol, twice a day versus aerosolized salbutamol, four times a day, in patients with stable asthma]

1 reference

12 December 2020

[The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, double-blind study]

1 reference

12 December 2020

Formoterol, a new long-acting bronchodilator for inhalation

1 reference

12 December 2020

Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma

1 reference

12 December 2020

Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma?

1 reference

12 December 2020

Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma

1 reference

12 December 2020

Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration

1 reference

12 December 2020

Bronchial hyperreactivity

1 reference

12 December 2020

Eformoterol and bronchial hyperresponsiveness in mild asthma

1 reference

12 December 2020

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

12 December 2020

Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics

1 reference

12 December 2020

Clinical evaluation of isopropyl-epinephrine in management of bronchial asthma

1 reference

12 December 2020

Effect of solution and suspension type aerosol of formoterol on tremor response and airways in patients with asthma

1 reference

12 December 2020

Neue broncholytisch hochwirksame Körper der Adrenalinreihe

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

7 January 2021

inferred from DOI database lookup

Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006923.PUB3

7 January 2021